Anthropometric Measurements as Predictors of Low Birth Weight Among Tanzanian Neonates: A Hospital-Based Study
November 7, 2025
Free CME credits
Both our subscription plans include Free CME/CPD AMA PRA Category 1 credits.
Brand Name :
Javlor  
Synonyms :
vinflunine
Class :
Cytotoxic Chemotherapy 
Brand Name :
Javlor  
Synonyms :
vinflunine
Class :
Cytotoxic Chemotherapy 
Dosage forms& StrengthsÂ
Solution  Â
25mg/ml Â
Administer a dose of 320 mg/m2 via infusion up to 20 minutes one time for every three weeks
Safety and efficacy studies are not establishedÂ
CYP3A strong enhancers of the small intestine may reduce the bioavailability of vinflunine
vinflunine is known to increase the risk of peripheral neuropathy when combined with lipegfilgrastim
it may increase the levels of serum concentration of OATP1B1/1B3 (SLCO1B1/1B3) Substrates
it may increase the levels of serum concentration of OATP1B1/1B3 (SLCO1B1/1B3) Substrates
it may increase the levels of serum concentration of OATP1B1/1B3 (SLCO1B1/1B3) Substrates
it may increase the levels of serum concentration of OATP1B1/1B3 (SLCO1B1/1B3) Substrates
it may increase the levels of serum concentration of OATP1B1/1B3 (SLCO1B1/1B3) Substrates
it may diminish the excretion rate when combined with vinca alkoloids, resulting in an enhanced serum level
may decrease the levels of serum concentration
may decrease the levels of serum concentration
may decrease the levels of serum concentration
may decrease the levels of serum concentration
may decrease the levels of serum concentration
may increase the levels of serum concentration
may increase the levels of serum concentration
may increase the levels of serum concentration
may increase the levels of serum concentration
may increase the levels of serum concentration
when lenograstim is coupled with vinflunine, the risk or severity of peripheral neuropathy can be enhanced
Actions and spectrum:Â
Vinflunine binds to a protein which makes up the microtubules and leads to the inhibition of assembly of microtubules. This interference with the formation of the microtubule disrupts the mitotic spindle apparatus thus leading to the arrest of cell cycle and inhibition of cell division.Â
Black box warningÂ
No specific black box warning is availableÂ
Contraindications/CautionÂ
ContraindicationsÂ
Known hypersensitivityÂ
CautionsÂ
Renal impairmentÂ
Pre-existing cardiovascular conditionsÂ
Pregnancy & breastfeeding:Â
Pregnancy consideration:Â
US FDA pregnancy category: Not assignedÂ
Breastfeeding warnings:Â
Data about the excretion of the drug into human milk is not knownÂ
Pregnancy category:Â
Pharmacology:Â
Vinflunine is an alkaloid obtained from the plant Vinca. It is a cytotoxic agent and indicated in chemotherapy to treat cancer of urothelial tract.Â
Pharmacodynamics:Â
Vinflunine’s protection against tumors is determined by the level and length of exposure to this drug. Meanwhile, it decreases microtubule assembly through inhibition of microtubules formation at micromolar concentrations that lowered growth rate and extent of microtubule. In terms of power and rate of extension of microtubules, vinflunine has notable antitumor activities against various human xenografts in mice. Compared to other vinca alkaloids, vinflunine’s effects on tumors have been extensively evaluated in animal models with impressive therapeutic gains. Â
Pharmacokinetics:Â
Absorption:Â
This drug possesses a linear pharmacokinetic profileÂ
Distribution:Â
The drug has a large terminal volume of distribution of about 35L/kg (2422± 676L). About 67.2± 1.1% of the drug is known to be bound to plasma proteins.Â
Metabolism:Â
It undergoes hepatic metabolism mostly by cytochrome P4503A4 but DVFL (4-O-deacetylvinflunine) will be formed slowly.Â
Excretion:Â
About two thirds of the drug is eliminated through feces and remaining one third in urine.Â
Half-life:Â Â
40 hoursÂ
Administration:Â
This drug should be administered directly into the blood stream through an intravenous route.Â
Patient information leafletÂ
Generic Name: vinflunineÂ
Why do we use vinflunine?Â
This drug is an antimitotic and antitumor agent indicated in treating certain cancers especially employed in the treatment of TCC (transitional cell carcinoma) of the urothelial tract. This is also found to be useful in patients who have not responded to platinum-containing chemotherapy.Â
Both our subscription plans include Free CME/CPD AMA PRA Category 1 credits.
On course completion, you will receive a full-sized presentation quality digital certificate.
A dynamic medical simulation platform designed to train healthcare professionals and students to effectively run code situations through an immersive hands-on experience in a live, interactive 3D environment.
When you have your licenses, certificates and CMEs in one place, it's easier to track your career growth. You can easily share these with hospitals as well, using your medtigo app.
